Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Cathie Wood Loads Up On Tempus AI And This George Soros-Backed Company's Stock, Dumps Roku And Shopify Shares
10:16pm, Monday, 05'th Jan 2026
On Monday, Jan. 5, 2026, Cathie Wood-led ark purchased Tempus AI and Kodiak AI shares while selling Roku and Shopify stock
Tempus AI (NASDAQ:TEM) & Healthcare Triangle (NASDAQ:HCTI) Head-To-Head Review
02:48am, Monday, 05'th Jan 2026
Healthcare Triangle (NASDAQ: HCTI - Get Free Report) and Tempus AI (NASDAQ: TEM - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses base
How Tempus AI Is Building Scale While Near-Term Risks Persist
08:35am, Tuesday, 30'th Dec 2025
TEM is scaling via growing multi-quarter bookings, but delayed revenue conversion, MRD competition and rising losses keep near-term risks in focus.
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside
09:50am, Monday, 29'th Dec 2025
Tempus AI and Hims & Hers are riding healthcare IT growth, but diagnostics scale and consumer demand set different upside paths.
How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up
08:21am, Friday, 26'th Dec 2025
TEM sees modest Q3 reimbursement gains, but FDA and ADLT pathways for xT, xF and xR assays could narrow its pricing gap over 2025-2026.
Tempus AI Approaching Profitability Despite GAAP Losses
08:41am, Friday, 19'th Dec 2025
TEM shows early profitability inflection with first positive Adjusted EBITDA in Q3 2025, raised revenue guidance and disciplined spending despite GAAP losses.
Tempus AI: A Healthcare Hyper-Growth Opportunity For The Risk Tolerant
07:05am, Thursday, 18'th Dec 2025
Tempus AI (NASDAQ:TEM) is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive precision medicine via AI and ML. TEM delivered 85% YoY revenue growt
Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
12:26pm, Wednesday, 17'th Dec 2025
Tempus AI posts first positive adjusted EBITDA as genomics testing accelerates and data bookings broaden. Zacks Rank #3 (Hold) with mixed Style Scores.
Tempus AI: Plenty Of Growth Catalysts Ahead, Grab It While It's Down
10:13am, Tuesday, 16'th Dec 2025
Tempus AI remains a Buy after a market-driven correction, with operational performance and partnerships strengthening the long-term thesis. TEM's organic revenue grew 28% y/y, gross margins improved 4
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
10:11am, Tuesday, 16'th Dec 2025
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
3 MedTech Stocks Poised to Gain in 2026 From the AI Boom
09:16am, Tuesday, 16'th Dec 2025
AI is reshaping MedTech, and Stryker, Tempus AI and GE HealthCare are emerging as key players leveraging AI across surgery, diagnostics and imaging.
Tempus AI Near $75 Target? Valuation, Upside and Risks
12:30pm, Monday, 15'th Dec 2025
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
Frontier Capital Management Co. LLC Sells 69,958 Shares of Tempus AI, Inc. $TEM
04:14am, Friday, 12'th Dec 2025
Frontier Capital Management Co. LLC lowered its stake in Tempus AI, Inc. (NASDAQ: TEM) by 10.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange C
Tempus AI's Strategic Push to Expand Beyond Oncology
08:11am, Thursday, 11'th Dec 2025
TEM extends its AI tools beyond oncology, adding FDA-cleared cardiac and ECG software plus key acquisitions to deepen its diagnostic reach.
Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition?
08:41am, Wednesday, 10'th Dec 2025
Tempus AI's shift toward scalable revenues, high-margin data services and broader AI capabilities defines a pivotal moment for TEM investors.
